newsfilter
← Latest News
GlobeNewswire·

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

ELAB
  • NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced positive Phase III results from its AI-driven drug discovery partnership with Yuva Biosciences.
  • Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells.
  • Four AI-selected compounds (C1, C2, C3, & C4) demonstrated statistically significant increases in ANT1 protein expression, which is central to skeletal muscle energy metabolism.
  • Candidates C1, C2, & C4 were identified as the strongest & most dose-consistent ANT1 inducers, with C2 showing up to +50% induction & C4 showing up to +48%.
  • Candidate C3 also advanced as a viable option due to statistically significant activity observed at the highest tested dose (+29% increase).
  • The results support moving the four validated candidates into confirmatory testing within a more mature skeletal muscle model to further de-risk development.
  • These findings align with the Company's broader strategy to develop muscle preservation therapies, including potential applications for use with weight loss treatments.
  • NorthStrive Biosciences & Yuva Biosciences are currently evaluating next steps to advance the four candidates through further characterization & development.